Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
HSD17B13 Inhibitor
HSD17B13-IN-60 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. This compound is primarily utilized in research related to liver and metabolic diseases, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its inhibition of HSD17B13 makes it a valuable tool for understanding the underlying mechanisms of these disorders and developing potential therapeutic strategies. -
17β-HSD Inhibitor
HSD17B13-IN-18 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol and less than 1 μM for Leukotriene B3. This compound is significant in the context of nonalcoholic fatty liver diseases (NAFLDs), particularly in the study of nonalcoholic steatohepatitis (NASH). HSD17B13-IN-18 facilitates research aimed at understanding and potentially therapeutically targeting metabolic disorders related to liver function. -
17β-HSD1 Inhibitor
3-Acetyl-7-Hydroxycoumarin is a selective inhibitor of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1). It exhibits significant biological activity, demonstrating 57% inhibition of 17β-HSD1 at a concentration of 6 μM. This compound is valuable for research applications focused on hormone-dependent diseases, including breast cancer and endometriosis. -
HSD17B13 Inhibitor
HSD17B13-IN-94 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. This compound is instrumental in the investigation of liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its selective inhibition of HSD17B13 provides valuable insights into the underlying mechanisms of these diseases. -
AKR1C3 Inhibitor
S07-2005 (racemic) is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor, exhibiting an IC50 value of 0.13 μM for AKR1C3 and 0.75 μM for AKR1C4. This compound demonstrates significant potential as a chemotherapeutic potentiator, particularly in overcoming resistance mechanisms in cancer treatment. Its selectivity and efficacy make it a valuable tool for research applications focused on cancer biology and drug resistance mechanisms. -
HSD17B13 Inhibitor
HSD17B13-IN-56-d3 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for investigating the role of HSD17B13 in liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its inhibitory action makes it a significant tool for exploring therapeutic strategies targeting these conditions. -
17β-HSD Inhibitor
HSD17B13-IN-36 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol as a substrate. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH), making it valuable for research concerning metabolic disorders and liver health. Its selective inhibition of HSD17B13 may provide insights into therapeutic interventions for liver-related diseases. -
HSD17B13 Inhibitor
HSD17B13-IN-98 is a potent inhibitor of 17 β-hydroxysteroid dehydrogenase (HSD17B13), demonstrating an IC50 value for estradiol of less than 0.1 μM. This compound is particularly relevant in the investigation of nonalcoholic fatty liver disease, providing valuable insights into the biochemical pathways involved in lipid metabolism and liver function. Its specificity and efficacy make it an essential tool for research focused on metabolic disorders and related therapeutic strategies. -
HSD17B13 Inhibitor
HSD17B13-IN-59 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research focused on liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its specific mechanism of action makes it an essential tool in elucidating the role of HSD17B13 in various pathophysiological contexts. -
17β-HSD1 Inhibitor
7-Coumaryl triflate is a selective inhibitor of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1), demonstrating an IC₅₀ of 360 nM and a Kᵢ of 173 nM. This compound selectively targets 17β-HSD2 while displaying no significant affinity for estrogen receptors ERα or ERβ. 7-Coumaryl triflate is valuable for research focused on hormone-dependent breast cancer and the modulation of estrogen metabolism. -
HSD17B13 Inhibitor
HSD17B13-IN-26 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). This compound exhibits significant activity in the modulation of steroid metabolism and demonstrates potential therapeutic applications in liver diseases, including hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma. Researchers can utilize HSD17B13-IN-26 to further investigate the role of HSD17B13 in liver pathology and associated metabolic disorders. -
17β-HSD Inhibitor
4'-Hydroxyvalerophenone is a specific inhibitor of 17β-hydroxysteroid dehydrogenase (17β-HSD), exhibiting an IC50 value of 60.52 μM. This compound plays a significant role in steroid metabolism and can be utilized in various research applications related to hormonal regulation and steroid biosynthesis. Its inhibitory effects make it a valuable tool for studies investigating the role of 17β-HSD in physiological and pathological processes. -
17β-HSD5 Inhibitor
17β-HSD5 inhibitor 1 is a potent inhibitor of 17β-HSD5, demonstrating an IC50 of 2.9 nM in HEK-293 cells that overexpress human 17β-HSD5. This compound is primarily utilized in research applications related to steroid metabolism and is instrumental in studying the modulation of sex steroid biosynthesis. The selective inhibition of 17β-HSD5 can provide insights into its role in various hormonal disorders and therapeutic interventions. -
17β-HSD5 Inhibitor
17β-HSD5 inhibitor 2 is a potent inhibitor of 17β-hydroxysteroid dehydrogenase 5 (17β-HSD5), demonstrating an IC50 value of 40 nM. This compound is valuable for research into steroid metabolism and androgen biosynthesis, with potential applications in studying conditions related to hormone regulation and prostate cancer. Its inhibitory action enables the exploration of therapeutic strategies targeting 17β-HSD5 in various biological contexts. -
CHI3L1 Inhibitor
CHI3L1-IN-1 is a selective inhibitor of Chitinase-3-like protein 1 (CHI3L1), also known as YKL-40, with an IC50 of 50 nM. This compound exhibits additional effects by inhibiting the hERG channel with an IC50 of 2.3 μM. CHI3L1-IN-1 is valuable for research applications focused on the roles of CHI3L1 in inflammation and cancer, offering insights into its potential as a biomarker and therapeutic target. -
CYP2D6 Inhibitor
Guanfu base A is a potent noncompetitive inhibitor of CYP2D6, with a Ki value of 1.20 μM in human liver microsomes and 0.37 μM for the recombinant form. This antiarrhythmic alkaloid, derived from Aconitum coreanum, also exhibits competitive inhibition of CYP2D in monkey and dog microsomes, with Ki values of 0.38 μM and 2.4 μM, respectively. In addition to its CYP2D6 inhibitory activity, Guanfu base A demonstrates the ability to inhibit HERG channel current, making it relevant for studies in drug metabolism and cardiac electrophysiology. -
CYP2D6 Inhibitor
Guanfu base A hydrochloride is a selective inhibitor of the CYP2D6 enzyme, demonstrating significant potential in the management of arrhythmia-related disorders. This alkaloid exhibits inhibitory effects across various species, including humans, primates, and canines. Its ability to modulate CYP2D6 activity may provide valuable insights and therapeutic applications in pharmacology and toxicology research. -
5-LOX Inhibitor
5-O-Demethylnobiletin is an effective inhibitor of 5-lipoxygenase (5-LOX), exhibiting a potent IC50 of 0.1 μM without impacting COX-2 expression. This polymethoxyflavone, derived from Citrus jambhiri Lush., demonstrates notable anti-inflammatory properties by inhibiting leukotriene B4 (LTB4) production in rat neutrophils and elastase release in human neutrophils with an IC50 value of 0.35 μM. 5-O-Demethylnobiletin is valuable for research applications related to inflammation and leukotriene signaling pathways. -
5-LO Inhibitor
Enofelast (BI-L-239) is a selective inhibitor of 5-lipoxygenase (5-LO) with an IC50 of 2.48 μM, effectively blocking calcium ionophore-induced leukotriene B4 (LTB4) production. Its ability to modulate lipid mediators makes it a valuable tool for studying inflammatory pathways and leukotriene signaling in various biological contexts. Enofelast is suitable for research applications investigating the role of 5-LO in diseases associated with inflammation and immune response. -
PA2/5-LOX/COX Inhibitor
LY256548 is a potent inhibitor of phospholipase A2, 5-lipoxygenase (5-LOX), and cyclooxygenase (COX), demonstrating significant anti-ischemic and anti-inflammatory properties. This compound effectively reduces leukotriene B4 production in response to A23187 stimulation. In preclinical models, LY256548 has shown efficacy in mitigating bone damage and paw swelling in rat models of Freund's complete adjuvant-induced arthritis (FCA), making it a valuable tool for research into inflammatory diseases and analgesic mechanisms. -
Cyclooxygenase/Lipoxygenase Inhibitor
L-652343 is a dual inhibitor of cyclooxygenase and lipoxygenase enzymes. It effectively inhibits the production of leukotriene B4 (LTB4) in isolated human polymorphonuclear leukocytes, demonstrating an IC50 value of 1.4 μM when challenged with Calcimycin. This compound is applicable in the study of inflammatory and immune diseases, providing insights into the mechanisms of these conditions and potential therapeutic interventions. -
5-LO Inhibitor
5-LOX-IN-6 is a potent and selective inhibitor of 5-lipoxygenase (5-LO), exhibiting reversible inhibition. It effectively reduces 5-LO activity in human neutrophils and recombinant human 5-LO with IC50 values of 0.23 µM and 0.086 µM, respectively. By inhibiting leukotriene biosynthesis, 5-LOX-IN-6 serves as a valuable tool in the study of inflammatory and allergic disorders. -
5-LOX Inhibitor
E 6080 is a specific inhibitor of 5-lipoxygenase (5-LOX), exhibiting an IC50 of 0.2 μM in rat basophilic leukemia cells. This compound effectively reduces leukotriene release, which is critical in the inflammatory response. E 6080 has demonstrated the ability to inhibit bronchospasm induced by antigen inhalation in sensitized guinea pigs, making it a valuable tool for asthma research and related inflammatory conditions. -
5-LOX Inhibitor
A63162 is a selective inhibitor of 5-lipoxygenase (5-LOX), a key enzyme in the biosynthesis of leukotrienes. This compound effectively inhibits both mitogen-induced proliferation of horse mononuclear cells and the synthesis of leukotriene LTB4 in response to Calcimycin at equivalent concentrations. A63162 is useful in research focused on chronic obstructive pulmonary disease, arthritis, and inflammatory bowel disease, offering insights into inflammatory pathways and potential therapeutic interventions. -
CETP Inhibitor
Obicetrapib is a potent cholesteryl ester transfer protein (CETP) inhibitor that effectively reduces atherogenic lipoproteins, including LDL-C, ApoB, and lipoprotein(a), while simultaneously increasing HDL-C levels. This compound is of significant interest in research related to dyslipidemia and atherosclerotic cardiovascular disease (ASCVD), facilitating investigations into lipid metabolism and cardiovascular health outcomes. -
PPO Inhibitor
PPO-IN-10 is a selective inhibitor of protoporphyrinogen IX oxidase (PPO), functioning through its 2-phenylpyridine pyrrolidone scaffold. By inhibiting PPO, this compound induces the accumulation of photosensitive protoporphyrin IX, ultimately leading to necrosis in target weed leaves. PPO-IN-10 serves as a valuable tool in research aimed at the development of novel PPO herbicides. -
Protoporphyrinogen IX Inhibitor
PPO-IN-2 is a potent inhibitor of protoporphyrinogen IX oxidase, exhibiting a Ki value of 16 nM. This compound effectively disrupts heme biosynthesis by targeting the conversion of protoporphyrinogen IX to protoporphyrin IX. PPO-IN-2 is valuable for research into porphyrias and other disorders related to heme metabolism, providing insights into potential therapeutic strategies. -
PPO Inhibitor
PPO-IN-3 is a potent protoporphyrinogen oxidase (PPO) inhibitor, exhibiting a KI value of 0.67 nM. This compound demonstrates effective post-emergence herbicidal activity, making it valuable for agricultural applications aimed at weed control. Its specific mechanism of action provides a useful tool for research into herbicide efficacy and resistance mechanisms. -
Protoporphyrinogen Oxidase Inhibitor
Herbicidal agent 2 is a protoporphyrinogen oxidase (PPO) inhibitor that demonstrates effective herbicidal activity against a range of broadleaf and monocotyledon weeds. This compound serves as a valuable tool in agricultural research for studying herbicide resistance and developing new weed management strategies. Its targeted mechanism offers insights into the inhibition of crucial enzymatic pathways involved in plant growth and development. -
PPO Inhibitor
PPO-IN-7 is a potent inhibitor of protoporphyrinogen oxidase (PPO), a key enzyme involved in heme biosynthesis. This compound demonstrates significant herbicidal activity, making it valuable for research applications in plant biology and agricultural chemistry. Its ability to inhibit PPO provides insights into metabolic pathways and offers potential development avenues for herbicide formulations. -
PPO Inhibitor
PPO-IN-6 is a potent protoporphyrinogen oxidase (PPO) inhibitor that disrupts heme and chlorophyll biosynthesis. By inhibiting PPO activity, PPO-IN-6 can be utilized in cancer research and the investigation of other diseases linked to altered porphyrin metabolism. This compound serves as a valuable tool for studying the biochemical pathways involved in disease progression and therapeutic interventions. -
PPO Inhibitor
PPO-IN-15 is a potent inhibitor of protoporphyrinogen IX oxidase (PPO), targeting a key enzyme in the biosynthesis of chlorophyll. This compound demonstrates effective herbicidal activity against resistant weed species, making it a valuable tool in agricultural research. Its selectivity profiles indicate reduced phytotoxicity, particularly in wheat and rice, enhancing crop safety while managing weed populations. This functionality makes PPO-IN-15 suitable for studies aimed at developing sustainable weed management strategies. -
PKM2 Kinase Inhibitor
PKM2-IN-3 is a selective inhibitor of the PKM2 kinase, demonstrating an IC50 value of 4.1 μM. This compound exhibits notable anti-neuroinflammatory effects by disrupting PKM2-mediated glycolysis and inhibiting NLRP3 activation. PKM2-IN-3 is suitable for research applications focused on metabolic regulation and neuroinflammation pathways. -
PKM2 Inhibitor
CIAC001 is a potent inhibitor of Pyruvate Kinase M2 (PKM2), demonstrating noteworthy anti-neuroinflammatory properties. It effectively suppresses LPS-induced nitric oxide (NO) production in BV-2 microglial cells, with an IC50 of 2.5 μM, and exhibits protective effects against neuroinflammation in various mouse models. Additionally, CIAC001 has shown the potential to inhibit aspects of chronic morphine-induced addiction, making it a valuable reagent for research into neuroinflammatory processes and addiction pathways. -
PKM2 Inhibitor
NPD10084 is a potent inhibitor of pyruvate kinase M2 (PKM2) that targets non-glycolytic signaling in cancer cells. By disrupting the interaction between PKM2 and key regulatory proteins such as β-catenin and STAT3, NPD10084 effectively inhibits downstream signaling pathways. This compound exhibits significant antiproliferative activity against colorectal cancer cells, making it a valuable tool for cancer research and therapeutic investigations. -
MRSA Pyruvate Kinase Inhibitor
Deoxytopsentin is a marine bisindole alkaloid that functions as an inhibitor of pyruvate kinase in methicillin-resistant Staphylococcus aureus (MRSA). This compound demonstrates significant antibacterial activity against MRSA strains in vitro. Deoxytopsentin is derived from sponges and serves as a valuable research tool for studying bacterial metabolism and developing therapies targeting antibiotic-resistant infections. -
AADC/PKM2 Inhibitor
Benserazide is an inhibitor of aromatic L-amino acid decarboxylase (AADC) and L-DOPA decarboxylase, primarily targeting the PKM2 enzyme. By binding directly to PKM2, Benserazide inhibits its activity, resulting in the suppression of aerobic glycolysis and the concurrent upregulation of oxidative phosphorylation (OXPHOS). This compound is valuable for research applications related to Parkinson's disease and melanoma. -
PKM2 Inhibitor
PKM2-IN-4 is a selective inhibitor of pyruvate kinase M2 (PKM2), exhibiting an IC50 of 0.35 μM. This compound is known to regulate pyruvate-dependent respiration and promotes mitochondrial H2O2 production, impacting the efficiency of the electron transport system. It serves as a valuable tool in research focused on metabolism, cancer biology, and oxidative stress. -
PKM2 Inhibitor
PKM2-IN-9 is a selective inhibitor of pyruvate kinase M2 (PKM2), achieving an inhibition rate of 75% at a concentration of 50 μM. This compound is of significant interest in cancer research, as it regulates metabolic pathways essential for tumor growth and survival. PKM2-IN-9 can be utilized to explore the role of PKM2 in cellular processes and as a potential therapeutic target in various types of cancer. -
Elk3 Inhibitor
Alkannin is a selective inhibitor of tumor-specific pyruvate kinase-M2 (PKM2), demonstrating potent activity without affecting PKM1 or pyruvate kinase-L (PKL). This compound has potential applications in cancer research, serving as a valuable tool for studying metabolic alterations in tumors and developing anticancer strategies. Alkannin's specificity for PKM2 highlights its utility in targeted therapeutic approaches in oncology. -
Pyruvate Kinase Inhibitor
PKM2-IN-5 is a selective inhibitor of pyruvate kinase M2 (PKM2), a critical enzyme involved in cellular energy metabolism. This compound exhibits potential for modulating glucose metabolism and influencing tumorigenesis by inhibiting PKM2 activity. PKM2-IN-5 is valuable for research applications in cancer biology and metabolic disorders, providing insights into the role of PKM2 in various cellular processes. -
Inverse RAR Inhibitor
BMS493 is an inverse pan-retinoic acid receptor (RAR) agonist that enhances nuclear corepressor interaction with RARs, effectively inhibiting retinoic acid-induced differentiation. This compound serves as a valuable tool in research applications focused on RAR signaling pathways and their regulatory mechanisms. Additionally, BMS493 features an alkyne group, enabling its use in click chemistry through copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules, facilitating diverse labeling and conjugation strategies. -
Nuclear Retinoic Acid Receptor γ Inhibitor
BMS270394 is a selective inhibitor of the nuclear retinoic acid receptor gamma (RAR-γ), exhibiting an EC50 of 30 nM for human RAR-γ. This compound demonstrates potent activity against RAR-β with an EC50 of 400 nM. BMS270394 is valuable in research applications focused on gene regulation, developmental biology, and potential therapeutic interventions related to retinoid signaling pathways. -
RAR/RXR Inhibitor
RXR Antagonist 5 is a selective retinoic acid X receptor (RXR) inhibitor, designed to modulate RXR activity. It effectively disrupts RXR signaling pathways, making it a valuable tool for investigating the role of RXR in various biological processes. This compound can be utilized in research applications focused on cancer biology, metabolism, and developmental studies, providing insights into RXR-mediated physiological functions. -
RAR/RXR Inhibitor
NBD-125 is a potent RAR/RXR inhibitor that modulates retinoic acid receptor signaling. It functions as an RXRα activator, demonstrating an IC50 of 31.10 μM in KM12C cells. This compound is valuable for research applications involving the regulation of gene expression and signaling pathways associated with nuclear receptor activity. -
RAR/RXR Inhibitor
AGN 191701 is a selective retinoic acid receptor (RAR) and retinoid X receptor (RXR) inhibitor. This compound has been shown to induce liver enlargement in rat models while preserving hepatocellular integrity, indicating a unique biological profile. AGN 191701 serves as a valuable tool for studying retinoid signaling pathways and their implications in hepatic processes. -
angiotensin-converting enzyme Inhibitor, renin Inhibitor
Lyciumin D functions as both an angiotensin-converting enzyme inhibitor and a renin inhibitor. This compound demonstrates significant potential in the modulation of the renin-angiotensin system, making it a valuable tool for research into hypertension and related cardiovascular conditions. Its multimodal mechanism can facilitate studies aimed at understanding blood pressure regulation and developing therapeutic strategies for hypertension management. -
Serine Protease Inhibitor
VD5123 is a potent serine protease inhibitor that effectively targets TMPRSS2, HGFA, matriptase, and hepsin, exhibiting IC50 values of 15 nM, 3980 nM, 140 nM, and 37 nM, respectively. This compound is particularly useful for antiviral research, including studies focused on SARS-CoV-2 and a broad spectrum of coronaviruses, as well as influenza viruses. Its ability to inhibit key proteases makes VD5123 an important tool in the investigation of viral pathogenesis and therapeutic development. -
Ser/Thr Protease Inhibitor
Nacresertib is a selective Ser/Thr protease inhibitor that targets specific proteolytic pathways within cells. This compound is pivotal in studying cellular signaling mechanisms and apoptosis, making it valuable for research focused on cancer and neurodegenerative diseases. Its ability to modulate protease activity allows for the exploration of therapeutic strategies in various pathological states. -
Sex Pheromone Inhibitor
iPD1 is a potent inhibitor of the sex pheromone cPD1, targeting pheromone signaling pathways. This compound effectively blocks the biological activity of sex pheromones, making it valuable in studies related to behavioral ecology and reproductive biology. Its application in research can provide insights into pheromone-mediated communication and its ecological impacts.
